Skip to main content
. 2023 Aug 25;18(8):e0289838. doi: 10.1371/journal.pone.0289838

Fig 1. Co-morbidities at baseline and endpoint for each of the 3 study cohorts: CKD3aA1, CKD3aA2, and CKD3aA3.

Fig 1

CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol.